Bonviva is an inhibitor of bone resorption, used for osteoporosis in postmenopausal women.
Release form and composition
Available drug in the form of film-coated tablets for oral administration and solution for intravenous administration.
The composition of Bonviv tablets include:
- 150 mg ibandronic acid;
- Excipients: lactose monohydrate, crospovidone, povidone K25, stearic acid 95, microcrystalline cellulose, anhydrous silicon colloid dioxide.
The composition of the film shell: hypromellose, talc, titanium dioxide (E171), macrogol 6000. Sometimes used ready-made mixture Opadry 00A28646 containing talc, titanium dioxide (E171) and hypromellose.
Tablets are sold in 1 or 3 pcs. in blister packs packed in cartons.
1 ml of Bonviv solution contains:
- 1 mg ibandronic acid;
- Auxiliary components: sodium chloride, sodium acetate trihydrate, glacial acetic acid and injectable water.
A solution of 3 ml in a syringe tube is supplied complete with a sterile injection needle in a plastic container.
Indications for use
As indicated in the instructions for Bonviva, this drug is prescribed for women with osteoporosis due to postmenopausal women. The goal of treatment is to prevent fractures.
According to the instructions for Bonviva, the use of this drug is contraindicated in:
- Damage to the esophagus, leading to a delay in its emptying, for example, with achalasia or stricture (for tablets);
- Hereditary intolerance to galactose;
- Lactase deficiency;
- Severe renal dysfunction (with CC up to 30 ml per minute);
- Glucose-galactose malabsorption;
- The incapacity of the woman is standing or sitting for 60 minutes after applying the drug;
- Hypersensitivity to ibandronic acid or any auxiliary component of the drug.
In the form of tablets with extreme caution, Bonviva is prescribed in the presence of active pathological processes localized in the upper GI tract, for example, for dysphagia, gastritis, an ulcer, duodenitis, established Barret esophagus or other diseases of the alimentary canal.
Dosing and Administration
In the form of tablets Bonviva take 1 pc. once a month (preferably on the same day) one hour before the first meal or liquid intake. The pill should be swallowed whole, not chewed or resolved (because there is a risk of ulceration of the upper GI tract), drinking plenty of drinking water (except for mineral water with a high calcium content) while sitting or standing. Within one hour after taking the drug can not go to bed.
If a woman for some reason missed the next intake of Bonviva medicine, she should drink the pill as soon as she remembers, but on condition that at least 7 days remain until the next intake. Further treatment should be carried out in accordance with the established schedule. If less than 7 days are left until the planned admission, then you need to wait for it and continue the therapy in accordance with the established schedule.
Bonviva solution is intended for intravenous administration. Injections should be carried out only by a medical specialist. One syringe tube contains a single dose of the drug - 3 mg ibandronic acid.
The solution is injected into the bolus once every three months. In case of skipping a regular injection, it is necessary to make it as soon as the woman remembers it. Next, the drug is continued with an interval of 3 months, focusing on the date of the last injection.
While using Bonviva, the following undesirable reactions from the body can be observed:
- Often (≥1 / 100 and <1/10): headache, esophagitis, nausea, gastritis, abdominal pain, gastroesophageal reflux disease, diarrhea, dyspepsia, skin rash, arthralgia, muscle spasms, musculoskeletal pain, myalgia, skeletal -muscle stiffness;
- Infrequently (≥1 / 1000 and <1/100): dizziness, dysphagia, ulceration of the esophagus or stricture, flatulence, vomiting, back pain, increased fatigue, inflammatory diseases of the eye (scleritis, uveitis, episclerosis);
- Rarely (≥1 / 10 000 and <1/1000): hypersensitivity reactions, duodenitis, swelling of the face, urticaria, angioedema.
In addition, transient flu-like symptoms often occur: chills, fever, arthralgia, myalgia, loss of appetite, nausea, bone pain, and increased fatigue. However, it is worth noting that in most cases the phenomena described were observed only after taking the first Bonviv pill, were characterized by weak or moderate intensity, short duration and passed on their own without the use of any corrective therapy.
During the period of use of Bonviva, it is recommended to additionally take vitamin D and calcium supplements, if the patient is receiving them in insufficient quantities.
During treatment, the drug requires monitoring of renal function, the content of serum calcium, magnesium and phosphorus.
Analogs Bonviva on the active substance are drugs Bondronat and Ibandronic acid Sandoz.
The following drugs related to the same pharmacological subgroup as Bonviva are related to the mechanism of action: Aklast, Actonel Alendronat, Alenthal, Aredia, Blaztera, Bonefos, Veroklast, Zolendronate-Teva, Zolendrax, Zelendronic-Rus 4, Zolériks, Klobir , Ksidifon, Lyndron, Ostalon, Ostealen, Ostepar, Pamidronat Medak, Pomegara, Rezoklastin FS, Resorba, Rizarteva, Rizendros, Strongos, Tevanat, Foroza, Fosamax.
Terms and conditions of storage
Bonviva is a drug that can be bought at a pharmacy only if you have a prescription prescribed by your doctor. According to the manufacturer’s recommendations, it should be stored in a place protected from sunlight, at temperatures up to 30 ºС. Under these conditions, the shelf life of tablets is 5 years, the solution - 2 years.